

Press Release

Araris Biotech appoints Bernd Schlereth as Chief Development Officer

Zurich, Switzerland, April 1st, 2021 – Araris Biotech AG, a company pioneering antibody-drug conjugate (ADC)-linker technology, announced today that it has recruited Dr. Bernd Schlereth as Chief Development Officer (CDO). He brings with him more than 20 years of experience in pharmaceutical drug development.

Between 2019 and 2021 Dr. Bernd Schlereth worked as Vice President Oncology Research at Molecular Partners AG. From 2013 to 2019 he was employed at Janssen/Covagen AG as Senior Director Nonclinical Development and between 2008 and 2013 as Associate Director Global Nonclinical Safety at Merck Serono. Prior to this, Dr. Schlereth worked for six years as Senior Director Pharmacology and Toxicology at Micromet, and he started in 2000 his career in industry at Bavarian Nordic.

In these positions he was responsible for the Discovery, Pharmacology, Toxicology and DMPK (Drug Metabolism & Pharmacokinetics) activities in close collaboration with CMC (chemistry, manufacturing, control), Clinical Development as well as Regulatory Affairs ensuring smooth and successful project transition from research into early and late-stage clinical development.

“I am very excited to join Araris Biotech and I am fascinated by the unique Araris linker technology.” said Bernd Schlereth, “In this respect, I really look forward to bring in my experience in drug development to establish and mature a robust and differentiated portfolio of clinical ADC product candidates.” Philipp Spycher, Araris’ CEO added, “We are very pleased to have strengthened our management team with Bernd Schlereth. He brings with him extensive knowledge of pharmaceutical development which will be tremendously valuable in helping to lead Araris Biotech forward towards the next stage of its evolution.”

Corporate contact:

Araris Biotech AG
Philipp Spycher, PhD, CEO
pspycher@ararisbiotech.com

About Araris Biotech AG:

Araris Biotech AG is a spin-off company from the Paul Scherrer Institute (PSI) and ETH Zurich focusing on the commercialization of a novel antibody-drug conjugate (ADC)-linker technology. Araris' innovative platform allows for the attachment of any payload to ‘off the shelf’ antibodies without the need of prior antibody engineering in a one-step process. The resulting ADCs have a well-defined drug-to-antibody ratio, are stable and monomeric. All these favorable properties contribute to the high efficacy, stability and low level of toxicity that have been observed so far. In summary, the straightforward drug conjugation, the versatility of the technology and the high in vivo efficacy enable the generation of ADC compounds for the treatment of patients with a high unmet medical need. For more information, please visit www.ararisbiotech.com.